PKU HealthCare Corp., Ltd.

This study aimed to investigate the pharmacokinetic characteristics of single fasting and postprandial oral administration of finerenone tablets (10 mg) developed and produced by Peking University Pharmaceutical Co., Ltd. in healthy study participants; finerenone tablets (Cosenta®, 10 mg) produced by Bayer AG were used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared.

This study aimed to investigate the pharmacokinetic characteristics of isavuconazole sulfate capsules (100 mg) developed and produced by Peking University Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal. Isavuconazole sulfate capsules (Kangxinbo®, 100 mg) licensed by Pfizer Australia Pty Ltd were used as the reference preparation. The pharmacokinetic parameters Cmax and AUC0-72 of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

This study aims to study the pharmacokinetic characteristics of tofacitinib citrate sustained-release tablets (11 mg) developed and produced by Peking University Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration; tofacitinib citrate sustained-release tablets (Xeljanz®, 11 mg) licensed by Pfizer Inc. and produced by Viatris Pharmaceuticals LLC were used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the human bioequivalence of the two preparations.